Why Genetic Testing Should Be Standard in Prostate Cancer
Clips
Hear why universal genetic testing matters in prostate cancer — plus, how it can improve treatment, equity, and outcomes for patients everywhere.
Genetic testing is no longer optional — it’s essential.
Welcome to the first episode of Labcorp Perspectives: Oncology, where host Dr. Rebecca Previs sits down with Sarah Young, a genetic counselor and Clinical Program Manager for Oncology at Labcorp, to talk about the growing importance of genetic testing in prostate cancer care.
Sarah shares insights from the recent American Urological Association (AUA) conference, where she helped lead the first plenary session focused on genetic testing in urologic oncology. Together, they discuss the latest research supporting universal germline testing, the clinical relevance of both germline and somatic testing, and how this information can directly influence treatment decisions, including eligibility for targeted therapies like PARP inhibitors.
They also explore barriers to adoption, including provider education gaps, complex guidelines, and limited access to genetics professionals, and offer practical solutions like mainstream testing, digital education tools, and Labcorp’s post-test counseling support.
Hear how broader testing strategies are reshaping care pathways, improving outcomes, and helping to close gaps for high-risk and historically underserved patient populations.